1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Rheumatoid Arthritis (RA: new trials by email Literature Review of Rheumatoid Arthritis (RA trials Research Report on Rheumatoid Arthritis (RA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis Placebo, Dapagliflozin (10mg Tab) - Rheumatoid Arthritis (RA | Phase 1 / Phase 2 | Not yet recruiting | Tanta University | 100 | 2026-10-30 | 2026-10-28 |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
Arthritis, Rheumatoid (2) · Myositis (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
Arthritis (2) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Immune System Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Rheumatic Diseases (2) · Skin and Connective Tissue Diseases (2) · Dry Eye Syndromes (1) · Eye Diseases (1) · Lacrimal Apparatus Diseases (1) · Mouth Diseases (1) · Muscular Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1)
dapagliflozin (1)
Artiva Biotherapeutics, Inc. (1) · Tanta University (1)
Brazil (1) · Bulgaria (1) · Egypt (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Portugal (1) · Romania (1) · Serbia (1) · Spain (1) · United States (1)